Advertisement

Spinal Tech

Device company Paradigm Spine has published two separate independent prospective clinical studies that examine the short- and long-term durability of coflex interlaminar stabilization. Here are four things to know about the two studies.

Stryker has sold its bone morphogenetic protein-7 assets to Mariel Therapeutics. The companies entered into a definitive agreement announced yesterday.

Advertisement
Advertisement